Department of Bioengineering and Therapeutic Sciences

Nevan Krogan, PhD

Tue Dec 8, 2015
Krogan.
QBI Director and Professor

As director of the Quantitative Biosciences Institute (QBI), I aim to create a framework that fosters open collaboration between scientists locally, domestically, and internationally, where each group brings something unique but highly complementary to the problem. At the onset of the current...

Artificial Kidney Research Advances Forward

Fri Nov 20, 2015

Nanotechnology Paves Way For Implantable Artificial Kidney

Fri Nov 20, 2015

Medication Revolution: FDA Approves 3-D Printing For Pills

Fri Nov 20, 2015

There’s a big racial disparity in NIH funding

Fri Nov 20, 2015

Abate honored by World Economic Forum at meeting in China

Wed Nov 18, 2015
Abate

Adam Abate, PhD

Faculty member Adam Abate, PhD, was selected by the World Economic Forum (WEF) as one of 45 exceptional Young Scientists—all under the age of 40—each of whom has contributed to advancing the frontiers of science, engineering, or technology in areas of high societal impact.

Department says farewell to Brodsky

Fri Nov 13, 2015
Brodsky in a hug with someone

Good wishes all around.

The Department of Bioengineering and Therapeutic Sciences bade a fond farewell to colleague and friend Frances Brodsky on Tuesday, November 10, 2015. At a royal-tea-party-themed send-off, Frances was toasted and feted with fond wishes and thanks for 28 years of dedicated service to UCSF.

Giacomini to lead largest study of genetic, ethnic differences in effectiveness of leading diabetes drug

Thu Nov 5, 2015
illustration of patient with diabetes
Thao P. Do

(left to right) The Galega officinalis (aka French lilac) was used as a folk remedy for diabetes symptoms for centuries before analysis of its extracts revealed compounds that lowered blood sugar. Eventually, metformin (molecule and pill) was developed. It is a related molecule that is longer acting and less toxic than the plant extracts. Metformin acts on cells in the liver (center and cross-section right) to reduce glucose production and thus blood sugar.

In people with type 2 diabetes, the body is less able to use the hormone insulin to regulate blood sugar. The disease affects 350 million patients globally—including 29 million in the United States, where it is the leading cause of blindness, kidney failure, and non-accident-related amputations.

Bioartificial Kidney: The Next Frontier in ESRD Treatment?

Thu Nov 5, 2015

Update from the Dean - Fall/Winter 2015

Tue Nov 3, 2015
Guglielmo
© majedphoto.com

Dean B. Joseph Guglielmo, PharmD
School of Pharmacy
University of California, San Francisco

Strategic planning; Recently received research funding: cancer, Alzheimer's, HIV, type 2 diabetes (Kroetz, Keiser, Gross, Roy); Recent faculty publications: fibrosis, biofilms, gout (DeGrado, Yang, Giacomini); Collaborations and partnerships; Patient care: SB 493, scope of practice for California...

Pages